ClinicalTrials.Gov Identifier | Biomarker(s) | Regimen | Phase | Sample Size | Stage | Primary Endpoint | Estimated or Actual Study Period [reference] |
---|---|---|---|---|---|---|---|
NCT02572843 | PD-L1 expression | Durvalumab + Cisplatin/Docetaxel +  | II | 68 | IIIA (N2) | EFS | June 16, 2016—December 2021 [76] |
NCT03425643 (KEYNOTE-671) | PD-L1 expression | Pembrolizumab + platinum doublet versus platinum doublet | III | 786 | IIB, IIIA | EFS, OS | April 24, 2018—June 29, 2026 |
NCT03456063 (IMpower-030) | PD-L1 expression | Atezolizumab + platinum doublet versus platinum doublet | III | 302 | II-IIIA, select IIIB (T3N2) | MPR | April 24, 2018—January 20, 2025 |
NCT02818920 (TOP1501) | PD-L1 expression | Pembrolizumab (neoadjuvant + adjuvant) | II | 32 | IB-IIIA | Surgical feasibility | January 2017 – March 2026 |
NCT04304248 (NeoTAP01) | PD-L1 expression | Toripalimab + albumin-bound Paclitaxel + Carboplatin | II | 30 | IIIA and IIIB with T3N2 disease | MPR | August 1, 2019—July 30, 2026 |
NCT04422392 | PD-L1 expression | Carboplatin, Pemetrexed or Nab-paclitaxel, PD-1 antibody | II | 107 | IIIA- N2 | PFS | July 13, 2020—June 30, 2025 |
NCT03480230 | PD-L1 expression | Compound 121,564 + chemotherapy depending on tumor histology | II | 60 | IB (tumor ≥ 4 cm in size, or grade 3, or with visceral pleura involvement), II or IIIA disease | ORR | June 26, 2018—November 2022 |
NCT04728724 | PD-L1 expression | Sintilimab ± chemotherapy | II | 100 | III | MPR | January 21, 2021—December 31, 2027 |
NCT03425643 | PD-L1 expression | Pembrolizumab + platinum doublet neoadjuvant chemotherapy | III | 786 | II, IIIA, and resectable IIIB (T3-4N2) | EFS, OS | April 24, 2018—June 29, 2026 |
NCT04865705 | PD-L1 expression | Tilelizumab + Albumin Paclitaxel + Carboplatin/Cisplatin | II | 33 | III (T2N2, T3-4N1-2) | R0 | November 10, 2020—June 10, 2022 |
NCT04326153 | PD-L1 expression | Sintilimab + Albumin paclitaxel + Carboplatin | II | 40 | IIIA | DFS | December 15, 2019—December 2022 |
NCT04638582 | PD-L1 expression | Pembrolizumab versus Pembrolizumab + platinum doublet chemotherapy | II | 44 | IA3, IB and IIA | ctDNA resolution | June 2021—March 2024 |
NCT04646837 | PD-L1 expression | Durvalumab + Paclitaxel + Carboplatin | I/II | 20 | IB-IIIA | MPR | May 2021—March 2025 |
NCT04586465 (DYNAPET) | PD-L1 expression | Pembrolizumab + Pemetrexed + Gemcitabine + Cisplatin + Carboplatin | II | 23 | IIA—IIIB | MPR, dynamic SUV change, ORR, uptake rate constant (Ki) | October 10, 2020—June 30, 2022 |
NCT03800134 (AEGEAN) | PD-L1 expression | Durvalumab + platinum-based chemotherapy | III | 800 | IIA to select IIIB | pCR, EFS | December 6, 2018—April 30, 2024 |
NCT04379635 | PD-L1 expression | Tislelizumab + Cisplatin/Carboplatin + Paclitaxel or Pemetrexed | III | 380 | II or IIIA | MPR, EFS | May 29, 2020—November 2025 |
NCT04338620 | PD-L1 expression | Camrelizumab + albumin-bound Paclitaxel and Cisplatin | II | 94 | IIIA-IIIB | pCR | March 12, 2020—November 2021 |
NCT04840290 | PD-L1 expression | Sintilimab + Platinum Doublet Chemotherapy | III | 30 | IIIA | ORR, R0 Resection Rate | June 1, 2019—June 1, 2023 |
NCT04699721 | PD-L1 expression | Nivolumab + Paclitaxel + Carboplatin | I | 40 | IIIA and IIIB (T3N2) | Adverse effects, surgical complications, non-R0 surgical events | July 1, 2020—December 2027 |
NCT04459611 (neoSCORE) | PD-L1 expression | Sintilimab + Chemotherapy | II | 60 | IB-IIIA | MPR | July 1, 2020—July 1, 2023 |
NCT04025879 | PD-L1 expression | Neoadjuvant Nivolumab + Platinum-based Doublet Chemo followed by Adjuvant Nivolumab | III | 452 | IIA-IIIB | EFS | September 16, 2019—September 30, 2024 |
NCT03732664 | PD-L1 expression | Nivolumab + Pembrolizumab | I | 40 | IA3 (≥ 2 cm), II and IIIA | Safety and adverse effects | October 1, 2018—October 31, 2027 |
NCT04541251 | PD-L1 expression | Camrelizumab + Nab-paclitaxel + Carboplatin | II | 40 | IB-IIIA | MPR | August 1, 2020—September 30, 2023 |
NCT04158440 | PD-L1 expression | Toripalimab + Platinum doublet chemotherapy | III | 406 | IIIA | MPR, EFS | November 1, 2019—May 31, 2025 |
NCT04316364 | PD-L1 expression | SHR-316 (anti-PD-L1 antibody) + Carboplatin + Paclitaxel | III | 456 | II, IIIA, IIIB | MPR, EFS | July 14, 2020—May 2026 |
NCT03916627 | PD-L1 expression | Cemiplimab + Platinum doublet (NSCLC cohort) | II | 94 | Not specified | MPR, STN, MTE | July 23, 2019—August 7, 2027 |
NCT04865250 (iReP) | PD-L1 expression | Atezolizumab + Carboplatin/nab Paclitaxel | II | 20 | II, IIIA, IIIB | MPR | January 7, 2021—December 30, 2024 |
NCT04348292 | PD-L1 expression | Durvalumab + Sirolimus | I | 31 | I, II, IIIa | Adverse events, pCR | March 10, 2021—December 25, 2025 |
NCT04560686 | PD-L1 expression TGF-beta | Bintrafusp Alfa | II | 23 | I-IIIA disease and IIIB (T3N2 only, and N2 single station) | MPR | August 5, 2020—October 1, 2024 |
NCT04061590 | PD-L1 expression | Pembrolizumab versus Pembrolizumab + Cisplatin/Pemetrexed | II | 84 | I-IIIA | Tumor-infiltrating immune cells (TIICs) | May 29, 2020—April 30, 2022 |
NCT04015778 | PD-L1 expression | Nivolumab + Carboplatin/ nab-Paclitaxel | II | 48 | IB-IIIA | MPR | August 8, 2019—July 2024 |
NCT04108013 | PD-L1 expression | SHR-1210 (PD-1 antibody) + Carboplatin + Paclitaxel-albumin | II | 38 | II-IIIA | MPR | October 8, 2019—July 31, 2021 |
NCT03623776 | PD-L1 expression | JS001 (Toripalimab) + Pemetrexed/Carboplatin | II | 80 | IB (≥ 4 cm), II and IIIA | DFS | February 1, 2019—March 1, 2024 |